The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea FDA to Review 7 Peptides for Compounding List in July 2026: BPC 157, Semax, Epitalon, and More HealingMaps An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica Peptides Lack Reliable Safety Information, Watchdog Warns